Today Anavex (AVXL) announced that it had obtained positive phase 2a results for its trial in treating patients with Alzheimer's. The reason why the results were positive was that the drug Anavex 2-73 was able to meet on the primary and secondary endpoints of the clinical study. In terms of the primary endpoint the company was determining whether or not the drug was safe and tolerable for patients. Anavex 2-73 displayed no adverse effects and was tolerable for all patients in the study. 

In terms of the secondary endpoint the company was looking at initial positive efficacy to determine if Anavex 2-73 has any type of effect in helping Alzheimer's patients. The secondary endpoint was not only met, but met on all standard measurement tests for Alzheimer's patients. These tests include: 

1. Cogstate Battery
2. Mini Mental State Examination -- MMSE
3. Event-Related Potentials 
4. P300 Tests 

In terms of the Event-Related Potentials -- ERP -- noted above all 32 patients tested in the study showed a p-value of p < 0.0007 . This is important because when Anavex released prior preliminary phase 2a results the ERP was lower. That means that from the last preliminary phase 2a results back in July 2015 to now the ERP score improved greatly. 

Further evidence that supports that the drug works is that all patients who finished the PART A portion of the study chose to enter the PART B portion of the study. Think about it if the drug wasn't working why would these patients want to go through another PART B study? We believe that the results posted by the company along with all patients wanting to enter the next study means that the drug is working well on improving patients with Alzheimer's.